NCT05785715: An ongoing trial by AbbVie
This trial is ongoing. It must report results 5 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05785715 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 24, 2023 |
| Completion date | May 30, 2025 |
| Required reporting date | May 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |